Our institution participates in clinical trials sponsored by EORTC, BIG, CECOG and several pharmaceutical companies. Currently, the accrual is in process for 2 phase II and for 12 phase III randomized controlled clinical trials evaluating new treatment modalities in solid tumor patients.The academic research solves selected problems of breast and colorectal cancer development. Among them, the detection of minimal residual disease and identification of risk factors for most prevalent malignancies are the major topics.